Logotype for WW International Inc

Weight Watchers (WW) Q2 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for WW International Inc

Q2 2026 earnings summary

5 Aug, 2026

Executive summary

  • Emerged from Chapter 11 bankruptcy in June 2025, applying fresh start accounting and establishing a new capital structure, resulting in non-comparable Predecessor and Successor periods.

  • Achieved ongoing progress in multi-year transformation, with improved financial footing, positive operating cash flow in Q2, and reaffirmed full-year 2026 revenue and adjusted EBITDA guidance.

  • Q2 2026 revenue was $162.3 million, down 14% year-over-year, driven by Behavioral declines but offset by strong Clinical growth.

  • Net income for Q2 2026 was $14.1 million, including a $4.6 million gain from debt extinguishment; diluted EPS was $1.41.

  • Leadership transition occurred in March 2026, with the CEO resigning and an Interim Office of the Chief Executive established.

Financial highlights

  • Q2 2026 revenue: $162.3 million (down 14% year-over-year); ARPU increased 10.2% to $20.90 due to a shift to higher-value tiers.

  • Clinical subscription revenue grew 30.4% to $39.9 million, now 24.6% of total revenue; Behavioral subscription revenue declined 22.7% to $121.5 million.

  • Q2 net income was $14.1 million; adjusted EBITDA was $39.8 million (24.5% margin); Q2 gross margin was 70.3%, with adjusted gross margin at 73.6%.

  • Marketing expense was $47.9 million (29.5% of revenue), higher than prior year due to reorganization.

  • Cash and cash equivalents at June 30, 2026, were $101.5 million.

Outlook and guidance

  • Full-year 2026 revenue guidance reaffirmed at $620–$635 million and adjusted EBITDA at $105–$115 million.

  • Clinical subscription revenue expected to represent 25–30% of 2026 total revenue.

  • Continued growth in Core+ subscribers and moderation in behavioral subscriber declines anticipated.

  • Expect positive operating cash flow for full year 2026; no need for additional liquidity anticipated in the next 12 months.

  • Management expects continued market disruption and competitive pressures, especially from rapid adoption of GLP-1 medications and new entrants.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Weight Watchers